Journal of Bioequivalence & Bioavailability

Biosimilar market overview, present and future

International Conference and Exhibition on Biowaivers & Biosimilars

September 10-12, 2012 Hilton San Antonio Airport, USA

Leandro Mieravilla

Scientific Tracks Abstracts: J Bioequiv Availab

Abstract:

Analyzed present and future actions of main players in biosimilar market in different regions of the world. After many years in the slow lane, changes are driving new momentum in the market for biosimilars. Strategies of main players oriented to growth in a new market. Patents for the first generation of approved biopharmaceuticals have either expired or are about to expire which open new opportunities at biopharmaceutical market. Thus the market is opening for generic versions, referred to as ?biosimilars? (European Union) or ?follow-on protein products? (United States). Healthcare professionals need to understand the critical issues surrounding the use of biosimilars to make informed treatment decisions. Cassara Biotech global development on biosimilar and biotechnology market. Biosimilars present a new set of challenges for regulatory authorities when compared with conventional generics.

Biography :

Leandro Mieravilla has completed his MBA at the age of 26 years after getting his BA orientated to global business development. He is Global Market Manager for Monoclonal Anti-Bodies for Cassara Biotech, a global biotechnology company. He has been working more than sixteen years in business development for Latin America and Asia-Pacific regions launching biotechnology and biosimilar products. He has been living and working in five countries and visited eighteen as global product manager in the beginning of his involvement in the pharmaceutical market in the 1990s. Now living in Canada and working for local and global markets, he has a great reputation on the biosimilar market.